{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:09:18Z","timestamp":1792598958317,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ophtha.2024.07.018","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T01:51:35Z","timestamp":1721353895000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Rate of Re-treatment in Patients Treated with Teprotumumab"],"prefix":"10.1016","volume":"132","author":[{"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7321-805X","authenticated-orcid":false,"given":"Emanuil","family":"Parunakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Malkhasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A.","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4591-5971","authenticated-orcid":false,"given":"Hannah L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tolentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne K.","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.07.018_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.ophtha.2024.07.018_bib2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2024.07.018_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2024.07.018_bib4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.07.018_bib5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.018_bib6","doi-asserted-by":"crossref","unstructured":"Douglas R, Holt R, Qashqai A, Ugradar S, Disruption of teprotumumab treatment in patients with thyroid eye disease (TED) is associated with increased retreatment rate, Thyroid, 2023;33(S1):P-1-A-124, DOI: 10.1089\/thy.2023.29156.abstracts.","DOI":"10.1089\/thy.2023.29156.abstracts"},{"key":"10.1016\/j.ophtha.2024.07.018_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","article-title":"Reactivation after teprotumumab treatment for active thyroid eye disease","volume":"263","author":"Hwang","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.018_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.018_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ophtha.2024.07.018_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ophtha.2024.07.018_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/bjophthalmol-2020-318314","article-title":"Improvement of asymmetric thyroid eye disease with teprotumumab","volume":"106","author":"Ugradar","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.018_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000003809","article-title":"Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab","volume":"9","author":"Ugradar","year":"2021","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.1016\/j.ophtha.2024.07.018_bib13","doi-asserted-by":"crossref","first-page":"101075","DOI":"10.1016\/j.ajoc.2021.101075","article-title":"Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases","volume":"22","author":"Chiou","year":"202117","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"8","key":"10.1016\/j.ophtha.2024.07.018_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2024.07.018_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent thyroid eye disease","volume":"31","author":"Patel","year":"2015","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.07.018_bib16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety and durability in longer duration thyroid eye disease and retreatment: Optic-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.018_bib17","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves\u2019 disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.ophtha.2024.07.018_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/IOP.0000000000001087","article-title":"Noninflammatory thyroid eye disease","volume":"35","author":"Ugradar","year":"2019","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.07.018_bib19","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1097\/IOP.0000000000001147","article-title":"Phenotypes of thyroid eye disease","volume":"34","author":"Uddin","year":"2018","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2024.07.018_bib20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.eprac.2022.06.003","article-title":"Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States","volume":"28","author":"Wang","year":"2022","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.ophtha.2024.07.018_bib21","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:43:56Z","timestamp":1734507836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024004299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0161642024004299"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Rate of Re-treatment in Patients Treated with Teprotumumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}